DETROIT Caraco Pharmaceutical Labs has launched bicalutamide tablets on behalf of Sun Pharma.
Bicalutamide tablets are an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone analog for the treatment of Stage D2 metastatic carcinoma of the prostate. This generic version of bicalutamide 50-mg tablets is bioequivalent to Casodex, which is a registered trademark of the AstraZeneca group of companies.
Daniel H. Movens, Caraco's CEO said, "We are pleased to add this product to our portfolio by launching bicalutamide tablets immediately to the marketplace. We continue to focus on working towards expanding our product offering as quickly and effectively as possible."
According to IMS Data, Casodex had U.S. sales of approximately $314 million for the calendar year of 2008.